PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin

Nephrology Dialysis Transplantation

Volumn 21, Issue 5, 2006, Pages 1270-1277

  Papavasiliou, Eleni C ^a   Gouva, Chariklia ^a   Siamopoulos, Kostas C ^a   Tselepis, Alexandros D ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Chronic kidney disease; Epoetin; Lipoproteins; Monocytes; PAF acetylhydrolase; Paraoxonase 1

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ARYLDIALKYLPHOSPHATASE 1; CALCIUM ION; CHOLESTEROL; CREATININE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPASE A2; RECOMBINANT ERYTHROPOIETIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CHRONIC DRUG ADMINISTRATION; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME RELEASE; FEMALE; FOLLOW UP; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; MALE; MONOCYTE; OUTPATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROBABILITY; PROGNOSIS; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33646169868     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfk043     Document Type: Article

References (28)

1. Schlondorff D, Neuwirth R. Platelet-activating factor and the kidney. Am J Physiol 1986; 251: F1-F11
2. Stahl RA, Thaiss F, Oberle G et al. The platelet activating factor receptor antagonist WEB 2170 improves glomerulal hemodynamics and morphology in a proliferative model of mesangial cell injury. J Am Soc Nephrol 1991; 2: 37-44
3. Jocks T, Freudenberg J, Zahner G, Stahl RA. Platelet-activating factor mediates monocyte chemoattractant protein-1 expression in glomerular immune injury. Nephrol Dial Transplant 1998; 13: 37-43
4. Tselepis AD, Chapman MJ. Inflammation, bioactive lipids and atherosclerosis: Potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl review 2002; 3: 57-68
5. Itabe H. Oxidized phospholipids as a new landmark in atherosclerosis. Prog Lipid Res 1998; 37: 181-207
6. Macphee CH, Moores K, Boyd H et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: Use of a novel inhibitor. Biochem J 1999; 338: 479-487
7. Stafforini DM, Elstad MR, McIntyre TM, Zimmerman GA, Prescott SM. Human macrophages secrete platelet-activating factor acetylhydrolase. J Biol Chem 1990; 265: 9682-9687
8. Packard CJ, O'Reilly DS, Caslake MJ et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000; 343: 1148-1155
9. Ballantyne CM, Hoogeveen RC, Bang H et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2004; 109: 837-842
10. Oei HS, van der Meer IM, Hofman A et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke. The Rotterdam study. Circulation 2005; 111: 570-575
11. Tsimihodimos V, Karabina S-AP, Tambaki A et al. Altered distribution of PAF-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res 2002; 43: 256-263
12. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 2005; 4: 193-205
13. Himmelfarb J. Linking oxidative stress and inflammation in kidney disease: Which is the chicken and which is the egg? Semin Dial 2004; 17: 449-454
14. Stenvinkel P, Ketteler M, Johnson RJ et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int 2005; 67: 1216-1233
15. Milionis HJ, Elisaf MS, Karabina S-AP, Bairaktari E, Tselepis AD, Siamopoulos KC. Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis prosedures. Kidney Int 1999; 56: 2276-2258
16. Raine AE, Margreiter R, Brunner FP et al. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 1992; 7: 7-35
17. Locatelli F, Aljama P, Barany P et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19: 1-47
18. Aguilera A, Selgas R. Effect of recombinant human erythropoietin on inflammatory status in dialysis patients. Nephrol Dial Transplant 2004; 19: V46-V53
19. Landray MJ, Wheeler DC, Lip GY et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: The chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 2004; 43: 244-253
20. Knight EL, Rimm EB, Pai JK et al. Kidney dysfunction, inflammation, and coronary events: A prospective study. J Am Soc Nephrol 2004; 15: 1897-1903
21. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in non-diabetic patients. Nephron 1997; 77: 177-185
22. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. Kidney Int 2004; 66: 753-760
23. Tsimihodimos V, Karabina SA, Tambaki AP et al. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol 2002; 22: 306-311
24. Oberg BP, McMenamin E, Lucas FL et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 69: 1009-1016
25. Cao Y, Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM. Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation. J Biol Chem 1998; 273: 4012-4020
26. Guerra R, Zhao B, Mooser V, Stafforini D, Johnston JM, Cohen JC. Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins. J Lipid Res 1997; 38: 2281-2288
27. Bryl E, Mysliwska J, Debska-Slizien A et al. The influence of recombinant human erythropoietin on tumor necrosis factor alpha and interleukin-10 production by whole blood cell cultures in hemodialysis patients. Artif Organs 1998; 22: 177-181
28. Bryl E, Mysliwska J, Debska-Slizien A et al. Recombinant human erythropoietin stimulates production of interleukin 2 by whole blood cell cultures of hemodialysis patients. Artif Organs 1999; 23: 809-816